Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares Repurchased
Ratios

Pharma-Bio Serv (PBSV) Accumulated Depreciation & Amortization (2016 - 2025)

Pharma-Bio Serv's Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $199929.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 69.63% year-over-year to $199929.0; the TTM value through Oct 2025 reached $199929.0, down 69.63%, while the annual FY2025 figure was $199929.0, 69.63% down from the prior year.
  • Accumulated Depreciation & Amortization reached $199929.0 in Q4 2025 per PBSV's latest filing, down from $658249.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $658249.0 in Q4 2024 to a low of $199929.0 in Q4 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $523732.0, with a median of $587089.0 recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 9.05% in 2022, then crashed 69.63% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $538384.0 in 2021, then grew by 9.05% to $587089.0 in 2022, then grew by 8.16% to $635009.0 in 2023, then grew by 3.66% to $658249.0 in 2024, then plummeted by 69.63% to $199929.0 in 2025.
  • Per Business Quant, the three most recent readings for PBSV's Accumulated Depreciation & Amortization are $199929.0 (Q4 2025), $658249.0 (Q4 2024), and $635009.0 (Q4 2023).